Navigation Links
Meeting highlights the role of molecular imaging biomarkers in clinical research and therapeutics
Date:10/1/2009

Reston, Va.SNM is collaborating with the International Partnership for Critical Markers of Disease (CMOD) during CMOD's 7th Annual Biomarkers and Surrogate Endpoints Symposium, Bethesda North Marriott Hotel and Conference Center, Bethesda, Md., Oct. 19󈞁, 2009. The joint session, co-hosted by SNM and CMOD, will be held on Wednesday, Oct. 21, from 12:30 p.m. to 4:15 p.m.

"We are pleased to further extend our collaboration with the International Partnership for Critical Markers of Disease by holding this joint session on molecular imaging biomarkers in clinical research," said Michael Graham, PhD, MD, SNM president and director of nuclear medicine at the University of Iowa Carver College of Medicine. "We have established a vital scientific partnership to promote the expanded use and validation of molecular imaging biomarkers for clinical trials. Improved availability and performance of molecular imaging biomarkers will facilitate the development of safe and effective therapeutic drugs and ultimately enhance the delivery of personalized medicine."

"Our common interest in accelerating scientific research and therapeutic drug development by creating novel and advanced biomarkers to promote optimal health care today is a model for others to follow," said Therese Heinonen, DVM, executive director and co-founder of the International Partnership for Critical Markers of Disease and associate director of scientific affairs, Montreal Heart Institute Coordinating Center. "SNM and CMOD share the vision of expanding the use of these biomarkers in a standardized clinical research environment where providing high-quality, cost-effective patient care is the ultimate goal."

Peter Libby (co-founder of CMOD and Mallinckrodt Professor of Medicine at Harvard Medical School and chief of cardiovascular medicine at Brigham and Women's Hospital) will moderate the special afternoon session with Michael Graham. Don Black, general manager of molecular imaging at GE Healthcare's Medical Diagnostics, and Alexander J.B. McEwan, MD, chair of the department of oncology at the University of Alberta, Canada, will present perspectives on standardizing molecular imaging clinical trials, with an emphasis on the challenges of developing molecular imaging agents and statistical considerations in trial design. The second panel, led by Dan Skovronsky, founder and CEO of Avid Pharmaceuticals, and Patricia Cole, executive director of Imagepace at Medpace, Inc., will discuss the potential role of molecular imaging biomarkers in therapeutic development in both oncology and neurologytwo areas of significant interest to clinicians, researchers and industry. The session concludes with presentations focused on challenges and opportunities for using molecular imaging biomarkers in clinical research.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Pelosi and Hoyer Remarks at Press Availability Following Leadership Meeting
2. 2009 American Association of Pharmaceutical Scientists Annual Meeting and Exposition
3. American Society of Plastic Surgeons hosts 78th annual meeting
4. American Society Of Plastic Surgeons Hosts 78th Annual Meeting
5. American Heart Association Meeting Report: High-Sugar Diet Increases Mens Blood Pressure; Gout Drug Protective
6. Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Guidelines on Cord Blood Education
7. Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
8. SpectraScience Announces Results of Annual Shareholder Meeting
9. Maternal/child health focus of African Science Academies meeting in Ghana Nov. 9-11
10. Allied Worlds Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting
11. Dean MacCarter, Ph.D. Addressed Differentiation of Responder vs Non-Responder CRT Status with Low Level Exercise at HFSA13th Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... “The Octagon of Spiritual Balances”: ... of Spiritual Balances” is the creation of published author, Pastor Bernard J. Weathers, pastor ... holds a bachelor degree in religious education and a master degree in theology. , ...
(Date:1/24/2017)... ... 23, 2017 , ... OSF Ventures, the corporate investment arm ... platform headquartered in Silicon Valley that connects startups to corporations and invests in ... three-year agreement to be a corporate sponsor of Plug and Play’s program for ...
(Date:1/24/2017)... ... January 23, 2017 , ... During the ... Carol Francis, Psychologist in the South Bay area , explained “Watching Women’s ... all people and by all people shines as a bright beacon of determination ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... translation and localization services for life science companies, has achieved ISO 17100:2015 ... TÜV SÜD America. ISO 17100 is the globally recognized standard that establishes ...
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters ... management and evaluation leaders with decades of experience who remain current practitioners in ... States healthcare system, there is a renewed demand for versatile, data-driven leadership.The American ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 7D Surgical announced today that ... U.S. Food and Drug Administration (FDA) and a ... North American commercial launch of its innovative Machine-vision ... the 7D Surgical System.  The ... and machine vision algorithms to eliminate the long-standing ...
(Date:1/23/2017)... and Markets has announced the addition of the "Needle Free Drug ... report to their offering. ... Highlights: The report provides a detailed analysis ... Market forecasts till 2025, using estimated market values as the ... Regions and Countries Key developments and strategies observed in ...
(Date:1/23/2017)... Alberta , January 23, 2017 ... del riñón (r enal) y ... sola dosis de a pabetalone    ... hoy los resultados preliminares de un ensayo en fase ... con discapacidad de riñón (renal) severa. Los datos demostraron ...
Breaking Medicine Technology: